

# Polyplex Corporation Limited - Q2 FY19 Result Update

Polyplex Corporation Ltd (PCL) is one of the world's largest manufacturers of thin Polyethylene Terephthalate (PET) film catering to Packaging, Industrial, Electrical & Imaging industry through its state-of-the-art manufacturing plants and distribution facilities in India, Thailand, Turkey and the US with a global market share of  $\sim 5\%$  in the thin PET film. PCL has a capacity of 186,000 MT of thin PET film and 28,800 MT of thick PET film which forms majority of the capacity.

### Q2 FY19 result beats our expectation; Margin saw improvement

- PCL's consolidated revenue increased by 36.0% YoY to INR 1,173.9 crore in Q2FY19
  on the back of higher sales volume, better realisation, value addition product and improved market conditions.
- The company's Operating EBITDA rose by 69.4% YoY to INR 208.3 crore in Q2FY19. Its Operating EBITDA margin expanded by 350 basis points to 17.75% in Q2FY19 on yearly basis. PCL's EBITDA too increased by 74.92% YoY to INR 229.76 crore in Q2FY19. EBITDA margin stood at 19.58% in Q2FY19 against 15.22% in Q2FY18.
- PCL's consolidated PAT was boosted by about 2.5x to INR 159.3 crore in Q2FY19 on YoY basis due to other income. The company's PAT margin saw an improvement of 597 basis points to 13.58% in Q2FY19.
- The company has successfully cut down its total debt by INR 151 cr to INR 587.75 crore in Q2FY19 from INR 783.7 crore in Q4FY18. Its total Debt to Equity ratio stood at 0.21x in Q2FY19 vs. 0.29x in Q4FY18.
- PCL's India operation witnessed top line growth of 37.35% YoY to INR 344.76 crore in Q2FY19. The company's Operating EBITDA margin remained flat at 7.65% in Q2FY19 against 7.55% in Q2FY18. Its PAT also grew by 60.36% YoY to INR 21.6 crore in Q2FY19. PCL's PAT margin expanded by 90 basis points to 6.27% in Q2FY19 on yearly basis.
- PCL's new Greenfield PET Film Line project with a capacity of 44,000 TPA along with Resin and Metallizing plant being setup by PT Polyplex Films Indonesia, at Indonesia is progressing as per schedule.
- The company has declared interim dividend of INR 10.
- The currency risk associated with Turkey business seems to have been stablised for now.

#### Valuation

PCL holds 51% stake in its listed subsidiary, Polyplex (Thailand) Public Corporation (PTL). PTL has a market capitalisation of  $\sim$ INR 3,200 crore and is available at 1.3x P/B. However, PCL has market cap of INR 1,967 crore and is available at P/B of 0.7x FY20E. PCL is trading at more than  $\sim$ 38.5% discount to PTL's market cap. At CMP, PCL is available at valuations of 1.9x FY20E EV/EBITDA. We recommend a Hold on PCL with target price of INR 672, valuing the stock at 3x EV/EBITDA .

Financials: (Consolidated) (In INR Cr.)

	,			'	
	FY 2016	FY 2017	FY 2018	FY 2019E	FY 2020E
Net Sales	3,202.0	3,201.0	3,572.3	3,994.0	4,450.0
EBDITA	386.9	563.5	538.3	627.5	716.4
PAT	16.3	361.4	284.1	320.6	392.4
EPS	9.1	72.4	49.9	56.2	68.9
EV/EBITDA	2.3	2.7	2.5	2.9	1.9

Source - DSPL Research, Company

RATING: HOLD

Target: 672 Upside: 10%

CMP: 613.45 (As on 15/11/2018)

Reuter Code : PLYP.NS Bloomberg Code : PPC IN

10.0
32.6
3.2
1,853.3
796.7
55,739
667.8
406.3
%
50.0
1.9
4.8
43.3

#### Sensex and Stock Movement



Dinesh Gupta +91 22 30272867

dinesh.gupta@dalmiasec.com

Lohit Bharambe +91 22 30272866

lohit.bharambe@dalmiasec.com



# Financials - Consolidated (in INR Cr.)

Particulars (in INR Cr)	Sep-18	Jun-18	q-o-q (%)	Sep-17	у-о-у (%)
Revenue from Operations (net)	1,173.5	1,065.0	10.2%	862.9	36.0%
Cost of Material Consumed	705.9	647.7	9.0%	508.1	38.9%
Purchases of stock-in-trade	33.7	35.0	-3.9%	27.9	20.8%
Changes in inventories	-34.8	-26.1		-26.2	
Gross Profit	468.7	408.5	14.7%	353.1	32.7%
Gross Profit Margin	39.9%	38.4%		40.9%	
Employee Benefits Expense	87.3	79.4	9.9%	75.8	15.3%
Power, Fuel & Water	63.7	57.4	11.0%	51.8	22.9%
Other Expenses	109.4	110.6	-1.1%	102.6	6.6%
Op. EBITDA	208.3	161.1	29.3%	122.9	69.4%
Op. EBITDA Margin	17.8%	15.1%		14.2%	
Other Income	21.5	47.2	-54.5%	8.4	154.9%
EBITDA	229.8	208.3	10.3%	131.4	74.9%
EBITDA Margin	19.6%	19.6%		15.2%	
Depreciation	51.0	49.8	2.5%	49.1	4.0%
EBIT	178.7	158.5	12.7%	82.3	117.2%
EBIT Margin	15.2%	14.9%		9.5%	
Finance Costs	7.7	9.2	-16.4%	7.9	-2.7%
PBT before exceptional item	171.1	149.3	14.5%	74.4	130.0%
Exceptional Items	0.0	0.0		0.0	
PBT	171.1	149.3	14.5%	74.4	130.0%
PBT Margin	14.6%	14.0%		8.6%	
Taxes	11.7	34.0	-65.4%	8.8	34.2%
Profit after Tax (PAT)	159.3	115.4	38.1%	65.6	142.7%
PAT Margin	13.6%	10.8%		7.6%	
Other comprehensive income	173.8	46.3	275.6%	63.6	173.2%
Total comprehensive income	333.1	161.6	106.1%	129.2	157.7%
Profit for the period attributable to:	159.3	115.4	38.1%	65.6	142.7%
Owner of the Parent	90.0	60.9	47.8%	35.8	151.3%
% of PAT	56.5%	52.8%		54.6%	
Non-controling Interest	69.3	54.5	27.3%	29.8	132.4%
% of PAT	43.5%	47.2%		45.4%	
F . D CI //ND					
Earnings Per Share (INR)	00.1	10.0	47.00/	11.0	151 00/
Basic	28.1	19.0	47.8%	11.2	151.3%
Diluted	28.1	19.0	47.8%	11.2	151.3%



# Financials - Consolidated (in INR Cr.)

Profit & Loss Statement	FY2018	FY2019E	FY2020E
Net Sales	3,572	3,994	4,450
Raw Material Cost	2,150	2,388	2,652
Gross Profit	1,423	1,606	1,798
Employee Cost	303	339	369
Other Manufacturing Cost	625	679	756
Operating EBITDA	494	588	672
Op. EBITDA Margin (%)	13.8%	14.7%	15.1%
Other Income	44	40	44
Deperication	185	211	225
EBIT	353	416	491
EBIT Margin	9.9%	10.4%	11.0%
Finance Cost	39	62	58
Exceptional Item	-	-	-
PBT	314	354	434
Tax	30	34	41
PAT	284	321	392
Less - Non-controling Interest	125	141	172
PAT after Non-controling interest	159	180	220
Share O/S (in cr)	3.2	3.2	3.2
Basic EPS (INR)	49.9	56.2	68.9
Diluted EPS (INR)	49.9	56.2	68.9
Cash EPS (INR)	107.7	122.2	139.2

Balance Sheet	FY2018	FY2019E	FY2020E
Share Capital	33	33	33
Reserves and Surplus	2,516	2,635	2,989
Shareholders Fund	2,548	2,668	3,022
Minority Interest	1,072	1,072	1,072
Total Loan	739	1,039	889
Deferred Tax Liailities	-	-	-
Total Liabilities	4,359	4,778	4,983
Net Fixed Assets	2,218	2,607	2,481
Capital work in Progress	8	8	8
Deferred Tax Assets	49	49	49
Goodwill	0	0	0
Investments	133	183	233
Sundry Debtors	550	569	622
Cash & Bank	781	990	1,222
Loans & Advances	24	24	24
Inventories	567	547	610
Other Current Assets	538	447	452
Total Current Assets	2,459	2,578	2,930
Sundry Creditors	267	317	354
Provision	10	28	31
Other Current Liabilities	231	301	335
Total Current liabilities &			
Provision	509	647	720
Net Assets	1,950	1,931	2,210
Total Assets	4,359	4,778	4,983

Cashflow Statement	FY2018	FY2019E	FY2020E
PBT	314	354	434
Depreciation & Amortization	185	211	225
Finance Cost	39	62	58
Others	21	-	-
(Incr)/Decr in Working Capital	(225)	229	(47)
Tax Paid	(27)	(34)	(41)
Cash Flow from Operating	307	823	628
(Incr)/ Decr in Gross PP&E	(138)	(600)	(100)
Others	11	(50)	(50)
Cash Flow from Investing	(126)	(650)	(150)
(Decr)/Incr in Share Capital	-	-	-
(Decr)/Incr in Debt	77	300	(150)
Interest Paid	(40)	(62)	(58)
Others	(50)	-	-
Dividend Paid	(29)	(201)	(38)
Cash Flow from Financing	(42)	36	(246)
Change in Currency Fluctuation Reserve			
arising on Consolidation	20	-	-
Incr/(Decr) in Balance Sheet Cash	159	209	232
Op Cash and cash equivalents	200	781	990
Cl. Cash and cash equivalents	359	990	1,222
Other Bank Balance	422	-	-
Cash & Bank	781	990	1,222

Ratios Analysis	FY2018	FY2019E	FY2020E
Per Share Value			
EPS (Rs)	49.9	56.2	68.9
BVPS (Rs)	796.7	834.0	944.7
DPS (Rs)	9.0	45.0	10.0
Turnover Ratio			
Inventory Days	51	51	47
Debtors Days	52	51	49
Creditors Days	27	27	28
Cash Conversion Cycle	76	75	69
Asset Turnover Ratio	0.7	0.7	8.0
Profitabiliy Ratio			
EBITDA Margin	15.1%	15.7%	16.1%
PAT margin	8.0%	8.0%	8.8%
ROA	5.8%	5.9%	6.9%
ROE	11.1%	12.0%	13.0%
ROCE	8.1%	8.7%	9.9%
Solvency Ratio			
Debt / Equity Ratio	0.3	0.4	0.3
Current Ratio	2.1	1.6	1.9
Quick Ratio	1.5	1.2	1.5
Interest Coverage Ratio	13.7	10.1	12.4
Valuation Ratios			
PE (x)	9.4	10.9	8.9
P/B (x)	0.6	0.7	0.6
EV/EBITDA (x)	2.5	2.9	1.9
Mcap/Sales (x)	0.4	0.5	0.4
Earning Yield (%)	10.6%	9.2%	11.2%
Dividend Yield (%)	1.9%	7.3%	1.6%
Free Cash Flow Yield (%)	8.6%	8.2%	24.0%

Source - DSPL Research

### **DISCLOSURE**

Investment Rating	Expected return (Over 1 year)
Buy	> 15%
Hold	> -10% to 15%
Sell	< -10%
Not Rated	We have forward looking estimates for the stock but we refrain from assigning recommendation

Trading Rating	Expected return (less than 1 year)
Buy	> 5%
Hold	> -5% to 5%
Sell	< - 5%

The definition of the terms used in making recommendations are available at http://www.dalmiasec.com/Pdf/Abbreviation.pdf. These terms have been consistently used throughout the Research Reports contained herein.

We/I, Dineshkumar Gupta, M. Sc, Lohit Bharambe, BE, PGPM, as author / the name subscribed to this report, hereby certify that all of the views expressed in this research report reflect my / our personal views about the subject or securities and no part of my / our compensation was / is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.. We / I or my / our relative(s) or Research Entity does not have any financial interest in the subject company other than disclosed.

Business activity of the research entity	Stock Broker, Merchant Banker, Depository Participant, Mutual Fund Distributor
Disciplinary history of the research entity	Nil

Terms & Conditions for offering Research Report by research entity

On principal, we do not sell our research reports.

The Research Report should be kept confidential.

The Research Report is published with honesty and in good faith.

The Research Report is prepared after thorough analysis of the Stock Market.

Research analyst or research entity shall effectively address conflict of interest which may affect the impartiality of its research analysis and research report and shall make appropriate disclosures to address the same.

Research analyst or research entity or any employees will not engage in insider trading or front running or front running of its own research report.

Research analyst or research entity shall comply with all regulatory requirements applicable to the conduct of its business activities.

Research analyst or research entity or its employees engaged in research analysis shall observe high professional standard while preparing research report.

Details of associate of research entity

Dalgreen Agro Pvt. Ltd.	Visual Estates Pvt. Ltd.	DSPL Investments Pvt. Ltd.	Chanda Bharech Beneficiary Trust	VSN Enterprises
Dalmia Investmart Pvt. Ltd.	Dalmia Devcon Pvt. Ltd.	Narain Prasad Dalmia HUF	Damia Devcon Pvt. Ltd.	Namtech Commercial LLP.
Dalmia Janakalyan Kosh	Sweta Beneficiary Trust	Suryakant Dalmia HUF	Mount Intra Finance Pvt. Ltd.	Vaishnawi Housing Pvt. Ltd.
Avni Beneficiary Trust	Dalmia Securities Pvt. Ltd. Employees Gratu- ity Fund	Mount Intra Properties LLP	Advay Beneficiary Trust	Mount Intra Finance Private Limited Employ- ees Gratuity Fund

### DISCLOSURE OF INTEREST:

Whether the research analyst or his relative or research entity or his associate has any financial interest in the subject company and the nature of such financial interest.	□ Yes	√ No
Whether the research analyst or research entity or its associates or relatives, have actual / beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report;	□ Yes	√ No
Whether the research analyst or research entity or its associates have received any compensation from the subject company in the past twelve months;	□ Yes	√ No
Whether the research analyst or research entity or its associates have managed or co-managed public offering of securities for the subject company in the past twelve months;	□ Yes	√ No
Whether the research analyst or research entity or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;	□ Yes	√ No
Whether the research analyst or research entity or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;	□ Yes	√ No
Whether the research analyst or research entity or its associates have received any compensation or other benefits from the subject company or third party in connection with the research report;	□ Yes	√ No
Whether the research analyst has served as an officer, director or employee of the subject company;	□ Yes	√ No
Whether the research analyst or research entity has been engaged in market making activity for the subject company.	□ Yes	√ No
Other Material Conflict of Interest, if any	N	L

### **DISCLAIMER**

This report has been prepared by M/s Dalmia Securities Pvt. Ltd. (hereinafter referred as DSPL, SEBI Registered Research Analyst) and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no quaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and DSPL is not soliciting any action based upon it. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. DSPL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not a guide for future performance. Investors are advised to see Risk Disclosure Document of each product before investing. DSPL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to real or potential conflicts of interest.

DSPL is registered under SEBI (Research Analyst) Regulations, 2014 vide Registration No INH300003066 dated 30.05.2016